Literature DB >> 19564361

Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis.

Bryan McGee1, Reynaldo Dietze, David Jamil Hadad, Lucilia Pereira Dutra Molino, Ethel Leonor Noia Maciel, W Henry Boom, Moises Palaci, John L Johnson, Charles A Peloquin.   

Abstract

Nineteen adults with pulmonary tuberculosis received linezolid (600 mg) once or twice daily in an early bactericidal activity trial. A one-compartment population model produced median values for the absorption rate constant, volume of distribution, and elimination rate constant of 1.5 h(-1), 29.6 liters, and 0.25 h(-1) (once daily) and 2.7 h(-1), 32.1 liters, and 0.15 h(-1) (twice daily). Linezolid administered twice daily produced higher values for free drug area under the concentration-time curve (AUC)/MIC and time above MIC. Both regimens achieved free AUC/MIC ratios > 100. Median times above the MIC for free drug were 100% (twice daily) and 63% (once daily).

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19564361      PMCID： PMC2737850          DOI： 10.1128/AAC.01378-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.

Authors:  M H Cynamon; S P Klemens; C A Sharpe; S Chase
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates.

Authors:  M Tato; E Gómez-G de la Pedrosa; R Cantón; I Gómez-García; J Fortún; P Martín-Davila; F Baquero; E Gomez-Mampaso
Journal:  Int J Antimicrob Agents       Date:  2006-06-13       Impact factor: 5.283

4.  Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation.

Authors:  W F Dodge; R W Jelliffe; J B Zwischenberger; R A Bellanger; J A Hokanson; W R Snodgrass
Journal:  Ther Drug Monit       Date:  1994-12       Impact factor: 3.681

5.  Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.

Authors:  Bent von der Lippe; Per Sandven; Oddbjørn Brubakk
Journal:  J Infect       Date:  2006-02       Impact factor: 6.072

6.  Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.

Authors:  I-Nae Park; Sang-Bum Hong; Yeon-Mok Oh; Mi-Na Kim; Chae-Man Lim; Sang Do Lee; Younsuck Koh; Woo Sung Kim; Dong Soon Kim; Won Dong Kim; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2006-07-19       Impact factor: 5.790

7.  Linezolid for the treatment of multidrug-resistant tuberculosis.

Authors:  Jesús Fortún; Pilar Martín-Dávila; Enrique Navas; Ma Jesús Pérez-Elías; Javier Cobo; Marta Tato; Elia Gómez-G De la Pedrosa; Enrique Gómez-Mampaso; Santiago Moreno
Journal:  J Antimicrob Chemother       Date:  2005-05-23       Impact factor: 5.790

Review 8.  Antimycobacterial activities of oxazolidinones: a review.

Authors:  R Sood; T Bhadauriya; M Rao; R Gautam; S Malhotra; T K Barman; D J Upadhyay; A Rattan
Journal:  Infect Disord Drug Targets       Date:  2006-12

9.  Linezolid in the treatment of osteomyelitis: results of compassionate use experience.

Authors:  C R Rayner; L M Baddour; M C Birmingham; C Norden; A K Meagher; J J Schentag
Journal:  Infection       Date:  2004-02       Impact factor: 3.553

10.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.

Authors:  Luis Alcalá; María Jesús Ruiz-Serrano; Cristina Pérez-Fernández Turégano; Darío García De Viedma; Marisol Díaz-Infantes; Mercedes Marín-Arriaza; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more
  28 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.

Authors:  Abdullah Alsultan; Jennifer J Furin; Jeannine Du Bois; Elana van Brakel; Phalkun Chheng; Amour Venter; Bonnie Thiel; Sara A Debanne; W Henry Boom; Andreas H Diacon; John L Johnson; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.

Authors:  N Bourgeois-Nicolaos; T T Nguyen; G Defrance; L Massias; L Alavoine; A Lefort; V Noel; E Senneville; F Doucet-Populaire; F Mentré; A Andremont; X Duval
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

4.  Distribution of Linezolid in Tuberculosis Lesions in Patients with Spinal Multidrug-Resistant Tuberculosis.

Authors:  Yuan Li; Weijie Dong; Tinglong Lan; Jun Fan; Shibing Qin; Ai Guo
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

5.  Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Authors:  Ashley D Hall; Molly E Steed; Cesar A Arias; Barbara E Murray; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

6.  Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.

Authors:  Tomohiro Sasaki; Hiroshi Takane; Katsuhiro Ogawa; Sayaka Isagawa; Takeshi Hirota; Shun Higuchi; Toshinobu Horii; Kenji Otsubo; Ichiro Ieiri
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

Review 7.  In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.

Authors:  Pavan K Vaddady; Richard E Lee; Bernd Meibohm
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

8.  Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.

Authors:  Michael A Lyons
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

9.  Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?

Authors:  G L Drusano; Brandon Duncanson; C A Scanga; S Kim; S Schmidt; M N Neely; W M Yamada; Michael Vicchiarelli; C A Peloquin; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

10.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.